Key Takeaways
- Carbon-14 radiolabelling has been crucial for understanding drug metabolism and pharmacokinetics in traditional drug development.
- Challenges arise in Carbon-14 radiolabelling of biological molecules due to their complex structure and metabolism.
- Regulatory expectations now adapt to include new therapeutic modalities, recognising the limitations of classical radiolabelling.
- Advances like accelerator mass spectrometry enable microtracer studies, allowing safer use of radiolabels with minimal doses.
- Future directions involve integrating new labelling techniques and technology to better study biological therapeutics and improve pharmacokinetic understanding.
Carbon-14 radiolabelling has long played a central role in understanding how drugs behave in the human body. For decades, radiolabelled studies have provided essential information on absorption, distribution, metabolism and excretion (ADME), helping regulators and pharmaceutical companies understand the fate of investigational medicines. The isotope carbon-14 remains the most widely used radiolabel in human mass-balance studies because of its stability within organic molecules and the sensitivity with which it can be detected.
However, as drug development shifts towards increasingly complex biological molecules, including peptides, monoclonal antibodies and oligonucleotide therapeutics, the traditional approach to carbon-14 radiolabelling faces significant scientific and practical limitations. At the same time, regulators have been refining expectations for radiolabelled studies, while analytical advances are opening new possibilities for studying drug metabolism using very small amounts of radioactivity.
Recent developments, therefore, reflect a transition in how carbon-14 radiolabelling is applied in pharmaceutical research. Updated regulatory guidance, new analytical technologies and the emergence of advanced therapeutic modalities are reshaping both the opportunities and the challenges associated with radiolabelled studies.
The Role of Carbon-14 in Drug Development
Carbon-14 has historically been the isotope of choice for radiolabelling small-molecule drugs. Its half-life of approximately 5,730 years means that it remains stable throughout the course of pharmacokinetic studies, while its chemical behaviour mirrors that of ordinary carbon atoms within organic compounds.
Radiolabelling with carbon-14 allows researchers to track the movement of a drug and its metabolites through the body by measuring radioactivity in biological samples such as blood, urine and faeces. This approach provides detailed information about how much of the drug is absorbed, how it is metabolised and how it is eliminated. These studies are typically referred to as human radiolabelled mass-balance studies.
In conventional drug development programmes, a carbon-14 labelled version of the investigational drug is administered to healthy volunteers, usually as a single oral or intravenous dose. Researchers then measure total radioactivity over time to determine the overall recovery of the dose and identify major metabolites.
Such studies are crucial for identifying metabolites that may require additional toxicological evaluation, particularly if they are present in humans at levels higher than those observed in animal models used in preclinical testing.
Regulatory Expectations for Radiolabelled Studies
Regulatory authorities have long recognised the importance of radiolabelled studies in drug development. In the United States, the U.S. Food and Drug Administration has provided detailed guidance on how such studies should be conducted to support new drug applications.
Recent regulatory developments have clarified expectations regarding the design and timing of human radiolabelled mass-balance studies. Updated guidance emphasises the need to obtain reliable information on drug elimination pathways and metabolite exposure early enough in development to support clinical decision-making.
The guidance outlines several important principles for radiolabelled studies. First, the radiolabel should be placed at a metabolically stable position within the molecule whenever possible. This helps ensure that the radioactive signal accurately reflects the presence of drug-related material rather than unrelated metabolic products.
Second, the total recovery of administered radioactivity should generally approach completion, typically above 90% of the administered dose. Achieving such recovery provides confidence that the major elimination routes have been characterised.
Third, metabolite identification should focus on compounds that represent a significant fraction of total circulating drug-related material. These metabolites may require additional safety evaluation if they are present at meaningful levels in humans.
While these expectations remain well established for small-molecule drugs, regulators increasingly recognise that applying the same principles to large biological therapeutics is not always straightforward.
The Rise of Biological Therapeutics
The pharmaceutical landscape has changed dramatically over the past two decades. Whereas most medicines once consisted of relatively small organic molecules, many modern therapies are now biological in nature. These include monoclonal antibodies, recombinant proteins, peptide therapeutics and nucleic-acid-based medicines such as antisense oligonucleotides.
Biologics often have molecular weights hundreds or even thousands of times those of traditional small-molecule drugs. Their mechanisms of action and metabolic pathways also differ significantly. Instead of being metabolised primarily by liver enzymes such as cytochrome P450 proteins, biologics are usually degraded by proteolytic enzymes within cells or in circulation.
This shift in therapeutic modalities has created new challenges for the application of traditional radiolabelling strategies.
Challenges in Carbon-14 Labelling of Biologics
One of the most significant difficulties in studying biological molecules using carbon-14 radiolabelling is the incorporation of the isotope into the molecule itself.
For small molecules synthesised through conventional organic chemistry, it is often possible to introduce a carbon-14 atom at a specific position within the structure. This ensures that the radioactive label remains associated with the molecule throughout most metabolic transformations.
In contrast, many biologics are produced using living cells rather than purely chemical synthesis. Recombinant proteins and monoclonal antibodies are typically expressed in mammalian or microbial cell cultures. Introducing carbon-14 into such molecules often requires the use of labelled amino acids during fermentation, resulting in the isotope being distributed across multiple positions within the protein.
This form of labelling can lead to several complications. Because the isotope is not located at a single defined position, protein degradation into smaller fragments may release labelled amino acids that enter normal metabolic pathways within the body. As a result, the radioactive signal detected in biological samples may not correspond directly to drug-related material.
In addition, the cost and complexity of producing radiolabelled biologics can be extremely high. Manufacturing large proteins or antibodies with sufficient radiochemical purity for clinical studies is technically demanding and may require specialised facilities.
Metabolic Complexity of Biological Molecules
Another major challenge arises from the way biologics are metabolised in the body. Small-molecule drugs often undergo well-defined metabolic transformations, such as oxidation or conjugation reactions, producing discrete metabolites that can be identified and quantified.
Biological molecules follow a very different path. Proteins and antibodies are typically internalised by cells and degraded into peptides and amino acids within lysosomes. These breakdown products may then be reused by the body to synthesise new proteins or enter other metabolic pathways.
If a biologic is labelled with carbon-14, the radioactive carbon atoms may appear in a wide range of endogenous molecules unrelated to the original drug. This phenomenon makes it difficult to determine how much of the detected radioactivity truly represents drug-derived metabolites.
Consequently, traditional mass-balance approaches that rely on measuring total radioactivity in excreta may provide limited insight into the pharmacokinetics of biologics.
Analytical Advances: Accelerator Mass Spectrometry
One of the most important technological developments in recent years has been the increasing use of accelerator mass spectrometry (AMS) for analysing carbon-14 labelled compounds.
AMS can detect extremely small amounts of carbon-14 with remarkable sensitivity. Whereas conventional liquid scintillation counting requires relatively large amounts of radioactivity, AMS can measure isotope ratios at levels approaching one part per trillion.
This capability has enabled the development of microtracer studies, in which very small amounts of carbon-14 labelled drug are administered to human volunteers. Because the radioactivity dose is extremely low, these studies expose participants to minimal radiation while still allowing highly sensitive detection of drug-related material.
Microtracer approaches are particularly useful when studying highly potent drugs or complex molecules where producing large quantities of radiolabelled material would be impractical.
Microtracer Studies in Clinical Pharmacology
In a typical microtracer study, a small amount of carbon-14 labelled drug is administered alongside a therapeutic dose of the unlabelled compound. Blood samples are collected over time and analysed using accelerator mass spectrometry to determine the pharmacokinetic profile of the labelled component.
This strategy allows researchers to measure parameters such as absolute bioavailability, clearance and metabolic pathways with minimal radiological risk. It also reduces the burden associated with manufacturing large batches of radiolabelled material.
Microtracer studies are increasingly being used in early clinical development to answer key pharmacokinetic questions. In some cases, they may even replace traditional radiolabelled mass-balance studies, particularly when the latter are technically challenging or scientifically uninformative.
Alternative Strategies for Studying Biologics
Because of the difficulties associated with carbon-14 radiolabelling of large biological molecules, researchers often employ alternative approaches to characterise their pharmacokinetics.
One common strategy involves the use of ligand-binding assays, such as enzyme-linked immunosorbent assays (ELISA), which can detect intact proteins or antibodies in biological samples. These methods provide direct measurement of circulating drug concentrations without relying on radioactive tracers.
Another approach involves stable isotope labelling, where non-radioactive isotopes such as carbon-13 or nitrogen-15 are incorporated into the molecule. Mass spectrometry can then be used to distinguish labelled drug molecules from endogenous compounds.
Radioiodination is also sometimes used for antibody studies, particularly in preclinical models, although this method introduces limitations due to the potential for deiodination.
Implications for Regulatory Science
Regulators increasingly recognise that the traditional framework for radiolabelled ADME studies may not apply equally to all therapeutic modalities. As biologics and advanced therapies become more prevalent, regulatory guidance is gradually adapting to reflect these differences.
Authorities now often accept alternative strategies for characterising the pharmacokinetics of biological drugs when classical radiolabelled studies are not feasible. These alternatives may include a combination of in vitro metabolism studies, animal studies using radiolabelled material and clinical pharmacokinetic analyses using non-radioactive methods.
The goal remains the same: to ensure that drug metabolism and elimination pathways are sufficiently understood to support safe and effective use in patients.
Future Directions in Radiolabelling Technology
Research into new radiolabelling techniques continues to expand. One promising area is site-specific labelling, in which isotopes are incorporated at carefully chosen positions within a molecule using advanced chemical or enzymatic methods. Such approaches may allow more precise tracking of biologics while minimising isotope redistribution.
Advances in analytical instrumentation are also likely to play an important role. Improvements in high-resolution mass spectrometry, combined with increasingly sensitive radiometric detection methods, are enabling more detailed characterisation of drug-related material in biological samples.
In the longer term, integrating radiolabelling data with computational and physiologically based pharmacokinetic modelling may provide a more comprehensive understanding of how complex medicines behave in the body.
Conclusion
Carbon-14 radiolabelling remains a cornerstone of drug metabolism research and regulatory science. For small-molecule drugs, radiolabelled mass-balance studies continue to provide critical information about pharmacokinetics and metabolic pathways.
However, the rapid expansion of biological therapeutics has exposed important limitations in the traditional use of carbon-14 labelling. Difficulties in incorporating the isotope into large molecules, combined with the complex metabolic fate of biologics, make classical radiolabelled studies challenging to interpret.
At the same time, advances in analytical technology, particularly accelerator mass spectrometry, are opening new possibilities for studying drug disposition using extremely small amounts of radioactivity. Microtracer studies and alternative analytical strategies are increasingly complementing or replacing traditional approaches.
As pharmaceutical science continues to evolve, the role of carbon-14 radiolabelling will likely become more specialised. Rather than disappearing, it is being integrated with modern analytical methods and adapted to meet the needs of an increasingly diverse range of therapeutic modalities.
Suggested Reading
References
amamoorthy A, Wang Y, Wang H, Prueksaritanont T. Human radiolabeled mass balance studies supporting the development of pharmaceuticals. Clin Transl Sci. 2022;15(8):1811–1823. Available from: https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13403
Cuyckens F, Balani SK, Leung KH, Lappin G. Recommendations on the use of multiple labels in human radiolabelled ADME studies. Drug Metab Dispos. 2024. Available from: https://www.sciencedirect.com/science/article/pii/S0090955624011309
Roffel AF, Lappin G, Garner RC. Phase 0 microdose and microtracer studies in early clinical drug development. Clin Transl Sci. 2024. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10982362
Lozac’h F, Sanders R, Saunders M. Evaluation of accelerator mass spectrometry for carbon-14 microtracer ADME studies. Bioanalysis. 2018;10(9):635–650. Available from: https://www.tandfonline.com/doi/full/10.4155/bio-2017-0216
Song Q, Turteltaub KW, Hattendorf B. Opportunities in low-level radiocarbon microtracing for biomedical research. Anal Bioanal Chem. 2015;407(11):3049–3058. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5137946/
Disclaimer
The information presented in this article is intended for educational and informational purposes only. It does not constitute regulatory, clinical, or professional advice. While every effort has been made to ensure accuracy, readers should consult official regulatory guidance and qualified experts when making decisions related to radiolabelling studies, drug development, or regulatory compliance. The views expressed are those of the author and do not necessarily reflect those of any regulatory authority or affiliated organisation.